Glaukos Corp (GKOS): Price-to-Revenue Ratio

Corporate company logo of Glaukos Corp. (GKOS)

A stable staff of leading ophthalmologists and engineers provides Glaukos Corporation (GKOS) with powerful scientific and technical potential. High business margins are based on the mass production of low-cost titanium chips following colossal R&D expenditures. Production localization in the US guarantees impeccable product quality, as confirmed by the company's average P/S: 21.10 shows the current value of this metric, helping to determine the risk of the asset being overbought.

Market Cap to Revenue: Glaukos Corporation (GKOS) for 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for Glaukos Corp (GKOS)

- market value and analyst target forecast:
Price Rate Chart Glaukos Corp|GKOS - Price Target Chart
- stock exchange capitalization data:
Market Value Glaukos Medical|GKOS - Enterprise Value
- issuer book value statistics:
Book Value per Share Glaukos|GKOS - Company Net Assets|Market Capitalization to Book Value Ratio glaukos.com|GKOS - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Glaukos Corporation|GKOS - Long-Term Debt to Equity|Current Liabilities to Capital glaukos.com|GKOS - Company Debts|Debts to Net Assets Glaukos Corporation|GKOS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Glaukos|Quick Liquidity Indicator glaukos.com
- company profitability and valuation multiples indicators:
GKOS - Company Net Income|Expected Net Profit Glaukos Corporation|GKOS - Price to Earnings Ratio|Future Price to Earnings Multiple Glaukos Medical|GKOS - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Glaukos|GKOS - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Glaukos|GKOS - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months glaukos.com|GKOS - Earnings growth in current year|Earnings growth forecast for next year Glaukos Corporation
- sales revenue and business income indicators:
GKOS - Company Sales|Company Projected Revenue Volume Glaukos|GKOS - P/S Multiple|Market Cap to Expected Sales Ratio Glaukos
Fundamental company analysis:GKOS, Glaukos Corp.
Signature product of Glaukos

The P/S ratio reflects the market value of each unit of revenue, allowing for an assessment of the premium paid for a business relative to its operating income. By analyzing the dynamics of the market capitalization-to-revenue ratio, an investor can see how the market values the scalability of Glaukos Corporation (GKOS) robotic implant production, where high engineering development costs and assembly automation determine the future potential for profit growth.

Who Glaukos Corporation competes with

Price-to-Revenue Ratio ALC (Alcon)|P/S Multiple BLCO (Bausch & Lomb)|APLS (Apellis Pharmaceuticals Inc) - Price-to-Sales Ratio|BLTE - Price-to-Revenue Ratio|OCUL - P/S Multiple|Harrow (HROW) - Price-to-Revenue Ratio|VRDN - Price-to-Revenue Coefficient|Market Cap to Revenue LENZ|Price to Sales Oculis AG OCS|P/S Multiple EYPT|KOD (kodiak.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALDX (Aldeyra Therapeutics Inc.)|Price-to-Revenue Coefficient KALA BIO, Inc. (KALA)|Opus Bio - P/S Multiple|OKYO - P/S Multiple|ADVM: P/S Multiple|OTLK: Market Cap to Sales Volume|Market Cap to Revenue CLSD|P/S Multiple novabay.com|Price-to-Revenue Ratio Kiora Pharmaceuticals Inc. (KPRX)|Price-to-Revenue Coefficient Alimera Sciences, Inc.|P/S Multiple EYEN (Eyenovia, Inc.)|P/S Multiple guardionhealth.com GHSI|OCUP - Price-to-Revenue Ratio|OPT (Opthea Ltd) - Market Cap to Revenue Ratio